Integrated Investment Consultants LLC Purchases 5,803 Shares of Abbott Laboratories $ABT

Integrated Investment Consultants LLC increased its position in Abbott Laboratories (NYSE:ABT) by 44.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,732 shares of the healthcare product maker’s stock after buying an additional 5,803 shares during the period. Integrated Investment Consultants LLC’s holdings in Abbott Laboratories were worth $2,347,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. J. Stern & Co. LLP raised its holdings in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank bought a new stake in Abbott Laboratories in the fourth quarter worth $2,938,892,000. Invesco Ltd. boosted its holdings in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares in the last quarter. Ninety One UK Ltd acquired a new position in Abbott Laboratories during the fourth quarter worth $336,815,000. Finally, Vanguard Group Inc. raised its holdings in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ABT. BTIG Research reiterated a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Mizuho cut their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Citigroup reduced their target price on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings cut Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, Argus lowered their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories Trading Up 0.1%

Shares of NYSE:ABT opened at $88.48 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock’s 50-day moving average is $90.08 and its 200-day moving average is $106.60. The company has a market cap of $154.12 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.